Geron Corporation (NASDAQ:GERN) is all set to report results for the first quarter closed March 31, 2017 on May 9, 2017. Last month, Blood Cancer Journal issued clinical efficacy and safety report on imetelstat from subjects with a form of MDS termed as RARS registered as part of the Mayo Clinic Pilot trial. The data comprised nine patients registered in the trial cohort, categorized as suffering with either IPSS intermediate-2 or intermediate-1 risk disease. 37.5% subjects who were needy of red blood cell transfusions at trial entry became transfusion independent for minimum 8 weeks.
At annual meeting of the American Association for Cancer Research in April, non-clinical report on imetelstat were showcased describing results from a trial in which imetelstat treatment of AML cell lines improved the effects of hypomethylating agents presently used for AML treatment.
Geron showcased results from non-clinical trials that offer further indication of potential on-target processes of telomerase inhibition by imetelstat causing the decline in platelets noted in previously performed imetelstat clinical studies.
At the American Society of Hematology yearly meeting in December, results related to the imetelstat plan were presented describing data from a non-clinical trial displaying that treatment with imetelstat extended overall survival of AML xenografts resultant from 9 out of 15 individual subject samples versus saline-treated controls.
An assessment of treatment patterns and results of subjects with MF from two U.S. medical health insurance claims records demonstrating a median overall survival of 7 months among subjects who discontinued or failed frontline ruxolitinib.
Telomere length dynamics from the previous Geron sponsored proof-of-concept trial in subjects with essential thrombocythemia representing that in 10 out of 13 subjects, telomere length in granulocytes was more after 9-months of cure with imetelstat and the change linked with the decline of JAK2V617F mutational burden, indicating that imetelstat may subdue neoplastic clones and support recovery of normal hematopoiesis in these subjects.